Adaptive Experimental Design Using Shrinkage Estimators
使用收缩估计量的自适应实验设计AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要明确以随机试验的处理分配和最终因果效应估计为目标,方法重点是实验设计与因果估计的联合改进。
使用收缩估计量的自适应实验设计AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
In multi-armed trials, adaptive designs are a popular way to increase estimation efficiency or identify optimal treatments. Several recent papers have proposed adaptive variants of the classical Neyman allocation to assign treatments in sequential trials, with the goal of minimizing the error of a Horvitz-Thompson-style estimator. However, this approach may be inefficient, because it fails to borrow information across the treatment arms. In this paper, we consider adaptivity in a sequential trial with K active treatments and a control, and suggest the use of Stein-like shrinkage estimators to obtain the final causal estimates. These estimators share information across arms, yielding provable reductions in expected squared error loss relative to estimating each causal effect in isolation. Moreover, for each of our candidate shrinkers, the risk is the expectation of ratios of Gaussian quadratic forms, and can be computed efficiently via numerical integration. Hence, we suggest a simple algorithm for sequential adaptivity: assign treatments to each new arrival by choosing the arm that will minimize the estimated shrinker loss. Through simulations, we demonstrate that this approach can yield meaningful reductions in estimation error, especially in the low signal-to-noise regime. We also characterize how our adaptive algorithm assigns treatments differently than would a sequential Neyman allocation, and suggest a method for constructing shorter confidence intervals at the trial's conclusion.